Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib in crizotinib-resistant ALK+ NSCLC (NP28761)
NCT01871805Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Sep 2013; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01871805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871805.